{"id":1013847,"date":"2026-10-27T06:14:04","date_gmt":"2026-10-27T10:14:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-to-measure-proteoforms-driving-alzheimers-disease-and-cancer-in-arpa-h-funded-seeds-consortium\/"},"modified":"2026-10-27T06:14:04","modified_gmt":"2026-10-27T10:14:04","slug":"nautilus-to-measure-proteoforms-driving-alzheimers-disease-and-cancer-in-arpa-h-funded-seeds-consortium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nautilus-to-measure-proteoforms-driving-alzheimers-disease-and-cancer-in-arpa-h-funded-seeds-consortium\/","title":{"rendered":"Nautilus to Measure Proteoforms Driving Alzheimer\u2019s Disease and Cancer in ARPA-H-Funded SEEDS Consortium"},"content":{"rendered":"

\nNautilus expects to receive up to $6 million to bring its Voyager\u2122 Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics
\n<\/h2>\n
\n

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (S<\/strong>equence-to-disease: E<\/strong>nvironment-aware E<\/strong>nsembles of D<\/strong>isordered proteins at S<\/strong>cale), a four-year, multi-center research consortium awarded up to $51.7 million by the Advanced Research Projects Agency for Health (ARPA-H). The consortium, which is co-led by the Buck Institute for Research on Aging<\/a> and Georgetown University<\/a>, aims to predict how disease-causing proteins misfold before irreversible damage occurs, and to use those predictions to develop new ways of detecting, slowing, and treating neurodegenerative diseases and cancer. Nautilus expects to receive up to $6 million over the duration of the program to deploy its Voyager Platform to measure proteoforms \u2013 the distinct versions of proteins that drive function \u2013 from model systems, disease tissues, and biofluids, starting with Alzheimer\u2019s disease and Ewing sarcoma.<\/p>\n

\u201cThe field knows more today about the downstream effects of protein misfolding than the upstream molecular causes. Nautilus\u2019 Iterative Mapping method is expected to provide an important tool to help us quantify the diverse proteoforms that may drive misfolding in the first place. Within SEEDS, we will apply the method to diseases where early intervention is critical,\u201d said Priyanka Joshi, Ph.D., Assistant Professor in the Department of Biochemistry and Molecular & Cellular Biology at Georgetown University School of Medicine and SEEDS co-lead.<\/p>\n

The genesis of pathologies such as Alzheimer\u2019s disease and cancer often lies in protein dysregulation, misfolding, and aggregation. SEEDS seeks to understand and predict the behavior of intrinsically disordered proteins implicated in these diseases. As many as half of human proteins may have intrinsically disordered regions whose shapes are constantly shifting. Because they lack the stable shapes and binding pockets that most drugs are designed to fit, they have been hard to study and have long been considered \u201cundruggable.\u201d Some of these protein shapes are prone to aggregation, leading to irreversible damage. Today, most treatments arrive only after that point, making earlier detection and intervention essential. SEEDS aims to address this challenge by developing diagnostics and therapeutics that enable earlier intervention. SEEDS is part of ARPA-H\u2019s BIOmolecular Grammar for protein Aggregation Modulation and Intervention<\/a> (BIOGAMI) program, which focuses on the earliest stages of protein dysfunction, and is led by ARPA-H Program Manager Shannon Greene, Ph.D.<\/p>\n

\u201cUnderstanding how protein folding changes patterns that drive disease has been critical in our field,\u201d said Chuankai (Kai) Zhou, Ph.D., Principal Investigator at the Buck Institute for Research on Aging and SEEDS co-lead. \u201cThe Nautilus Voyager\u2122 Platform is expected to give us a way to quantify how proteoforms contribute to distinct conformational states at high resolution, enabling us to determine how we might preempt disease progression before irreversible damage occurs.\u201d<\/p>\n

Within SEEDS, the Nautilus work under the program will support the study of proteoforms of tau and EWS::FLI1, proteins implicated in Alzheimer\u2019s disease and Ewing sarcoma, respectively, and is anticipated to extend to a larger set of intrinsically disordered proteins. The Voyager Platform is designed to analyze millions to billions of intact proteins independently and simultaneously at massive scale to quantify the complex dynamics of the proteoform landscape across disease processes. The large data corpus generated from these studies is expected to be used to train AI models to predict how proteoforms push a protein toward aggregation. SEEDS researchers may be able to use those predictions to design new diagnostics and therapeutics.<\/p>\n

Nautilus\u2019 participation in SEEDS builds on work already underway:<\/p>\n